Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

The twice-yearly shot lenacapavir, sold under the name Yeztugo, reportedly nearly eliminated new HIV infections in studies of ...

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced ...

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes ...

He highlighted that nearly 6,000 new HIV infections were recorded among individuals aged 15 to 24, describing the trend as deeply troubling. He said that syndemic diseases like HIV, TB and malaria ...

Medications to prevent HIV, known as pre-exposure prophylaxis, or PrEP, are widely available. But most are daily pills, including low-cost generic versions of Gilead’s older drug Truvada, that require ...

Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have struggled to ...

Washington (AFP) – The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the ...